Metabolic Syndrome and Risk of Acute Myocardial Infarction A Case-Control Study of 26,903 Subjects From 52 Countries

Population Health Research Institute, Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada.
Journal of the American College of Cardiology (Impact Factor: 15.34). 05/2010; 55(21):2390-8. DOI: 10.1016/j.jacc.2009.12.053
Source: PubMed

ABSTRACT This study examines the risk of acute myocardial infarction (MI) conferred by the metabolic syndrome (MS) and its individual factors in multiple ethnic populations.
The risk of the MS on MI has not been well characterized, especially in multiple ethnic groups.
Participants in the INTERHEART study (n = 26,903) involving 52 countries were classified using the World Health Organization (WHO) and International Diabetes Federation (IDF) criteria for MS, and their odds ratios (ORs) for MI were compared with the individual MS component factors.
The MS is associated with an increased risk of MI, both using the WHO (OR: 2.69; 95% confidence interval [CI]: 2.45 to 2.95) and IDF (OR: 2.20; 95% CI: 2.03 to 2.38) definitions, with corresponding population attributable risks of 14.5% (95% CI: 12.7% to 16.3%) and 16.8% (95% CI: 14.8% to 18.8%), respectively. The associations are directionally similar across all regions and ethnic groups. Using the WHO definition, the association with MI by the MS is similar to that of diabetes mellitus (OR: 2.72; 95% CI: 2.53 to 2.92) and hypertension (OR: 2.60; 95% CI: 2.46 to 2.76), and significantly stronger than that of the other component risk factors. The clustering of > or =3 risk factors with subthreshold values is associated with an increased risk of MI (OR: 1.50; 95% CI: 1.24 to 1.81) compared with having component factors with "normal" values. The IDF definition showed similar results.
In this large-scale, multi-ethnic, international investigation, the risk of MS on MI is generally comparable to that conferred by some, but not all, of its component risk factors. The characterization of risk factors, especially continuous variables, as dichotomous will underestimate risk and decrease the magnitude of association between MS and MI.

Download full-text


Available from: Shofiqul Islam, Jul 30, 2015
1 Follower
  • Source
    • "The metabolic syndrome is a clustering of cardiovascular risk factors, specifically obesity, hypertension, dyslipidemia and insulin resistance (Eckel et al., 2005), which has been associated with increased risk of cardiovascular disease (CVD) beyond traditional risk factors (Mente et al., 2010). The prevalence of metabolic syndrome is increasing in the United States (US) (Ford et al., 2002) and Europe in part paralleling the rising prevalence of obesity worldwide (Mente et al., 2010; Mokdad et al., 2003). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Increasing epidemiological evidence suggests independent associations between psoriasis and cardiovascular and metabolic disease. Our objective was to test the hypothesis that directly-assessed psoriasis severity relates to the prevalence of metabolic syndrome and its components. Population-based, cross-sectional study using computerized medical records from The Health Improvement Network Study population included individuals aged 45-65 years with psoriasis and practice-matched controls. Psoriasis diagnosis and extent were determined using provider-based questionnaires. Metabolic syndrome was defined using National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III criteria. 44,715 individuals were included: 4,065 with psoriasis and 40,650 controls. 2,044 participants had mild psoriasis (≤2% body surface area (BSA)), 1,377 had moderate (3-10% BSA), and 475 had severe psoriasis (>10% BSA). Psoriasis was associated with metabolic syndrome, adjusted odds ratio (OR) 1.41 (95% CI 1.31-1.51), varying in a “dose-response” manner, from mild (adj. OR 1.22, 95% CI 1.11-1.35) to severe psoriasis (adj. OR 1.98, 95% CI 1.62-2.43). Psoriasis is associated with metabolic syndrome and the association increases with increasing disease severity. Furthermore, associations with obesity, hypertriglyceridemia and hyperglycemia increase with increasing disease severity independent of other metabolic syndrome components. These findings suggest that screening for metabolic disease should be considered for psoriasis, especially when extensive.
    Journal of Investigative Dermatology 11/2011; 132(3 Pt 1):556-62. DOI:10.1038/jid.2011.365 · 6.37 Impact Factor
  • Source
    • "The clustering of cardiometabolic risk factors consisting of abdominal obesity, hypertension, insulin resistance, and dyslipidemia is called the metabolic syndrome (MetS; Zimmet et al., 2007). Adults with MetS have increased risk of developing type 2 diabetes mellitus and coronary heart disease (Mente et al., 2010; Zimmet et al., 2007). Obesity-related complications developed during childhood have been demonstrated to persist into adulthood, resulting in a higher incidence of type 2 diabetes mellitus and cardiovascular morbidity and mortality (Freedman, Khan, Dietz, Srinivasan, & Berenson, 2001; Zimmet et al., 2007). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Children with developmental coordination disorder (DCD) have higher rates of obesity compared to children with typical motor development, and, as a result may be at increased risk for developing metabolic syndrome (MetS). The purpose of this study was to determine the presence of MetS and its components among children with and without DCD. This nested case-control study classified 63 children scoring below the 16th percentile on the Movement Assessment Battery for Children (M-ABC-2) as probable DCD (pDCD), and 63 controls, all of whom scored above the 16th percentile. Metabolic syndrome was defined using the International Diabetes Federation (IDF) criteria. Eleven children met the criteria for MetS; 8 (72.3%) with pDCD and 3 (27.3%) controls (p = 0.115). Abdominal obesity was found in 39 (30.9%) of children, 29 (46.0%) with pDCD and 10 (15.9%) controls (p < 0.01). Serum triglycerides were higher in pDCD compared to controls, 91.9 mg/dl (63.1) vs. 67.7 mg/dl (33.3) in the control group, p = 0.001. Blood pressure was also significantly higher in the pDCD group, mean systolic BP (110 vs. 105 mmHg, p = 0.01) and mean diastolic BP (69 vs. 65 mmHg, p = 0.01). There were no statistically significant differences between the groups for other components of MetS. The higher prevalence of abdominal obesity and elevated triglycerides and blood pressure in children with pDCD may put them at risk of meeting all criteria of MetS earlier then their peers.
    Research in developmental disabilities 06/2011; 32(6):2785-9. DOI:10.1016/j.ridd.2011.05.030 · 4.41 Impact Factor
  • Source
    • "In a case-control study involving 393 early-onset coronary artery disease subjects, the prognostic information associated with the syndrome was not greater than the sum of its parts [33]. More recently, similar results were also reported in the INTERHEART study, a case-control study on the incidence of acute myocardial infarction involving more than 26,000 subjects in 52 countries [34] as well as in the RIVANA study, a population-based study involving 880 individuals [35]. In addition, the Rancho Bernardo Study, a community-dwelling sample of 338 participants with an average age of 67 years did not report any association between MetS and CVD [36]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The metabolic syndrome (MetS) is an insulin-resistant state characterized by a cluster of cardiovascular risk factors, including abdominal obesity, hyperglycemia, elevated blood pressure and combined dyslipidemia. In this review, we discuss the potential of farnesoid X receptor (FXR) agonists in the treatment of erectile dysfunction (ED), a multifactorial disorder often comorbid with MetS. FXR not only regulates lipid and glucose homeostasis but also influences endothelial function and atherosclerosis, suggesting a regulatory role for this hormone nuclear receptor in the cardiovascular complications associated with the MetS, including ED. MetS induces ED via several mechanisms, and in particular through endothelial dysfunction in penile vessels. In a high-fat diet rabbit model of MetS, a 3-month treatment with the potent and selective FXR agonist INT-747 restores endothelium-dependent relaxation in isolated cavernous tissue, normalizing responsiveness to acetylcholine and to electrical field stimulation. Accordingly, eNOS expression in the penis is greatly up-regulated by INT-747 treatment. Experiments in a rat model of chemically-induced type 1 diabetes further demonstrate that INT-747 treatment preserves erectile function induced by electrical stimulation of the cavernous nerve. These results add a new facet to the pleiotropic activities mediated by FXR, and reveal novel beneficial effects of FXR activation with potential clinical relevance. This article is part of a Special Issue entitled: Translating nuclear receptors from health to disease.
    Biochimica et Biophysica Acta 11/2010; 1812(8):859-66. DOI:10.1016/j.bbadis.2010.10.013 · 4.66 Impact Factor
Show more